Inclusion Criteria:

- Male and female participants

- Age 18-70 years

- Malignant melanoma stage II or III (>/= 1.5 mm tumor thickness, no distant metastases
or Malignant melanoma with lymph node metastases or Lymph node metastases with
unknown primary tumor

- An excision border of at least 2 cm around the primary tumor

- Therapy must start within 12 weeks after surgery of the tumor/of the lymph node
metastases

- ECOG status 0-1 (= Karnofsky Index >/= 80)

- Laboratory parameters

- Hematocrit >= 33%

- Leukocytes >= 3000/μl

- Thrombocytes >= 100000/μl

- Alanine aminotransferase(ALT) <= 2x normal values

- Bilirubin <= 2x normal values

Exclusion Criteria:

- Known allergy to one of the medications or any of its component parts

- Refusal on the part of participants capable of childbearing to use a reliable
contraceptive

- Lactating mothers

- Presence of distant metastases

- Another primary tumor of different histological origin than corresponding to the
indication (except when the relapse-free interval is > 5 years, or the tumor is a
cervical carcinoma in situ, a basal cell carcinoma or cutaneous squamous cell
carcinoma)

- Participants on corticosteroid treatment or treatment with an immunomodulating
substance

- Preexisting psychiatric illness, particularly serious depression

- Prior adjuvant radio-, chemo-, or immuno-therapy

- Treatment with an investigational drug within the prior 30 days

- Participant history that includes cardiac arrhythmia, cardiac insufficiency requiring
treatment, or anthracycline administration

- Myocardial infarction within the prior year

- An unstable medical condition (apart from the indication) that in the judgment of the
investigating physician excludes the participants from the study

- Psoriasis (a relative exclusion criterion, since interferon can aggravate psoriasis;
decision to be based on risk/benefit analysis)